Adenosine receptors in GtoPdb v.2021.2

Adenosine receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Adenosine Receptors [110]) are activated by the endogenous ligand adenosine (potentially inosine also at A3 receptors). Crystal structures for the antagonist-bound [153, 313, 221, 61], agonist-bound [375, 203, 204] and G protein-bound A2A adenosine receptors [49] have been described. The structures of an antagonist-bound A1 receptor [128] and an adenosine-bound A1 receptor-Gi complex [86] have been resolved by cryo-electronmicroscopy. Another structure of an antagonist-bound A1 receptor obtained with X-ray crystallography has also been reported [57]. caffeine is a nonselective antagonist for adenosine receptors, while istradefylline, a selective A2A receptor antagonist, is on the market for the treatment of Parkinson's disease.

[1]  Wei Liu,et al.  Cryo-EM structure of the human adenosine A2B receptor–Gs signaling complex , 2022, Science advances.

[2]  K. Jacobson,et al.  Structure-Activity Studies of 1H-Imidazo[4,5-c]quinolin-4-amine Derivatives as A3 Adenosine Receptor Positive Allosteric Modulators. , 2022, Journal of medicinal chemistry.

[3]  R. Stevens,et al.  GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for the A2A Adenosine Receptor , 2022, Journal of medicinal chemistry.

[4]  K. Jacobson,et al.  Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A3 Adenosine Receptor Homology Models and Structural Network Analysis Can Predict This Boundary. , 2021, Journal of Medicinal Chemistry.

[5]  James D. Clarke,et al.  Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity , 2020, Journal for ImmunoTherapy of Cancer.

[6]  M. Hung,et al.  ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis. , 2020, Cancer cell.

[7]  Peter Buneman,et al.  Why data citation isn't working, and what to do about it , 2020, Database J. Biol. Databases Curation.

[8]  Jeroen J. Bax,et al.  Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double‐blind, placebo‐controlled trial , 2019, European journal of heart failure.

[9]  J. Powers,et al.  Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers , 2019, Investigational New Drugs.

[10]  K. Varani,et al.  Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity. , 2019, Journal of medicinal chemistry.

[11]  Andrew P. Vreede,et al.  Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome , 2019, Nature Communications.

[12]  A. IJzerman,et al.  Development of Covalent Ligands for G Protein-Coupled Receptors: A Case for the Human Adenosine A3 Receptor , 2019, Journal of medicinal chemistry.

[13]  B. Kalthof,et al.  Novel non-xanthine antagonist of the A2B adenosine receptor: From HTS hit to lead structure. , 2019, European journal of medicinal chemistry.

[14]  K. Jacobson,et al.  Design and in Vivo Characterization of A1 Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series. , 2019, Journal of medicinal chemistry.

[15]  M. Kulka,et al.  Adenosine activates G&agr;s proteins and inhibits C3a‐induced activation of human mast cells , 2018, Biochemical pharmacology.

[16]  A. Hotson,et al.  A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models , 2018, Cancer Immunology Research.

[17]  W. Baumeister,et al.  Structure of the adenosine-bound human adenosine A1 receptor–Gi complex , 2018, Nature.

[18]  L. Peletier,et al.  A two‐state model for the kinetics of competitive radioligand binding , 2018, British journal of pharmacology.

[19]  Christopher G Tate,et al.  Cryo-EM structure of the adenosine A2A receptor coupled to an engineered heterotrimeric G protein , 2018, bioRxiv.

[20]  K. Garber Adenosine checkpoint agent blazes a trail, joins immunotherapy roster , 2017, Nature Biotechnology.

[21]  E. Segala,et al.  Structures of Human A1 and A2A Adenosine Receptors with Xanthines Reveal Determinants of Selectivity. , 2017, Structure.

[22]  S. Antonia,et al.  A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment , 2017, Neoplasia.

[23]  Nicole Diedrichs,et al.  Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist for the Chronic Treatment of Heart Diseases , 2017, ChemMedChem.

[24]  Arthur Christopoulos,et al.  Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity , 2017, Cell.

[25]  A. Leslie,et al.  Structure of the adenosine A2A receptor bound to an engineered G protein , 2016, Nature.

[26]  A. IJzerman,et al.  Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength. , 2016, Journal of medicinal chemistry.

[27]  X. García‐Mera,et al.  Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes. , 2016, Journal of medicinal chemistry.

[28]  A. Christopoulos,et al.  A Positive Allosteric Modulator of the Adenosine A1 Receptor Selectively Inhibits Primary Afferent Synaptic Transmission in a Neuropathic Pain Model , 2015, Molecular Pharmacology.

[29]  Axel Hoos,et al.  Big opportunities for small molecules in immuno-oncology , 2015, Nature Reviews Drug Discovery.

[30]  A. Leslie,et al.  Molecular Determinants of CGS21680 Binding to the Human Adenosine A2A Receptor , 2015, Molecular Pharmacology.

[31]  Wentao Zhang,et al.  Adenosine A2B receptor stimulates angiogenesis by inducing VEGF and eNOS in human microvascular endothelial cells , 2015, Experimental biology and medicine.

[32]  J. Powell,et al.  A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy , 2015, Computational and structural biotechnology journal.

[33]  Woody Sherman,et al.  Selecting an Optimal Number of Binding Site Waters To Improve Virtual Screening Enrichments Against the Adenosine A2A Receptor , 2014, J. Chem. Inf. Model..

[34]  Manuel de Lera Ruiz,et al.  Adenosine A2A receptor as a drug discovery target. , 2014, Journal of medicinal chemistry.

[35]  Joanne Baltos,et al.  Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist , 2014, Proceedings of the National Academy of Sciences.

[36]  B. Cronstein,et al.  Rolofylline, an adenosine A1 receptor antagonist, inhibits osteoclast differentiation as an inverse agonist , 2013, British journal of pharmacology.

[37]  C. Langmead,et al.  Pharmacology and Structure of Isolated Conformations of the Adenosine A2A Receptor Define Ligand Efficacy , 2013, Molecular Pharmacology.

[38]  Peter Kolb,et al.  Limits of Ligand Selectivity from Docking to Models: In Silico Screening for A1 Adenosine Receptor Antagonists , 2012, PloS one.

[39]  Woody Sherman,et al.  Current Assessment of Docking into GPCR Crystal Structures and Homology Models: Successes, Challenges, and Guidelines , 2012, J. Chem. Inf. Model..

[40]  H. V. van Vlijmen,et al.  Identifying novel adenosine receptor ligands by simultaneous proteochemometric modeling of rat and human bioactivity data. , 2012, Journal of medicinal chemistry.

[41]  R. Stevens,et al.  Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.

[42]  A. IJzerman,et al.  Functional efficacy of adenosine A2A receptor agonists is positively correlated to their receptor residence time , 2012, British journal of pharmacology.

[43]  Francesca Deflorian,et al.  Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. , 2012, Journal of medicinal chemistry.

[44]  K. Leineweber,et al.  Partial adenosine A1 receptor agonists for cardiovascular therapies , 2012, Purinergic Signalling.

[45]  Nathan Robertson,et al.  Article pubs.acs.org/jmc Identification of Novel Adenosine A 2A Receptor Antagonists by Virtual Screening , 2022 .

[46]  Jonathan S. Mason,et al.  Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design , 2012, Journal of medicinal chemistry.

[47]  S. Iwata,et al.  G protein-coupled receptor inactivation by an allosteric inverse-agonist antibody , 2011, Nature.

[48]  A. Bender,et al.  Substructure‐Based Virtual Screening for Adenosine A2A Receptor Ligands , 2011, ChemMedChem.

[49]  M. Congreve,et al.  Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. , 2011, Structure.

[50]  A. Leslie,et al.  Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation , 2011, Nature.

[51]  Kenneth A Jacobson,et al.  Recent developments in adenosine receptor ligands and their potential as novel drugs. , 2011, Biochimica et biophysica acta.

[52]  R. Stevens,et al.  Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.

[53]  B. Fredholm,et al.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update , 2011, Pharmacological Reviews.

[54]  B. Fredholm,et al.  Peripheral adenosine A2A receptors are involved in carrageenan-induced mechanical hyperalgesia in mice , 2010, Neuroscience.

[55]  K. Jacobson,et al.  Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. , 2010, Bioorganic & medicinal chemistry letters.

[56]  B. Fredholm,et al.  Adenosine A1 receptors (A1Rs) play a critical role in osteoclast formation and function , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[57]  K. Varani,et al.  Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes , 2010, British journal of pharmacology.

[58]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[59]  Judy Lin,et al.  Hybrid ortho/allosteric ligands for the adenosine A(1) receptor. , 2010, Journal of medicinal chemistry.

[60]  A. Ohta,et al.  The A2aR adenosine receptor controls cytokine production in iNKT cells , 2010, European journal of immunology.

[61]  Sergio Paredes,et al.  Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists. , 2010, Bioorganic & medicinal chemistry letters.

[62]  B. Fredholm,et al.  Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice. , 2010, Arthritis and rheumatism.

[63]  Ruben Abagyan,et al.  Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.

[64]  S. Masino,et al.  Control of Cannabinoid CB1 Receptor Function on Glutamate Axon Terminals by Endogenous Adenosine Acting at A1 Receptors , 2010, The Journal of Neuroscience.

[65]  K. Klotz,et al.  Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A3 receptor. , 2009, Journal of Medicinal Chemistry.

[66]  H. Yin,et al.  Genetic Deletion of A2A Adenosine Receptors in the Striatum Selectively Impairs Habit Formation , 2009, The Journal of Neuroscience.

[67]  Xiu Song,et al.  Preferential enhancement of working memory in mice lacking adenosine A2A receptors , 2009, Brain Research.

[68]  Farag F. Sherbiny,et al.  Homology modelling of the human adenosine A2B receptor based on X-ray structures of bovine rhodopsin, the β2-adrenergic receptor and the human adenosine A2A receptor , 2009, J. Comput. Aided Mol. Des..

[69]  B. Fredholm,et al.  Absence of adenosine A1 receptors unmasks pulses of insulin release and prolongs those of glucagon and somatostatin. , 2009, Life sciences.

[70]  J. Linden,et al.  Adenosine A2B receptors are highly expressed on murine type II alveolar epithelial cells. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[71]  Arthur Christopoulos,et al.  Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. , 2009, Journal of medicinal chemistry.

[72]  Thomas Borrmann,et al.  1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. , 2009, Journal of medicinal chemistry.

[73]  K. Jacobson,et al.  Novel 2- and 4-substituted 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor. , 2009, Journal of medicinal chemistry.

[74]  Dharini van der Hoeven,et al.  Characterization of the A2B Adenosine Receptor from Mouse, Rabbit, and Dog , 2009, Journal of Pharmacology and Experimental Therapeutics.

[75]  K. Klotz,et al.  N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice. , 2009, Journal of medicinal chemistry.

[76]  R. Greene,et al.  Control and Function of the Homeostatic Sleep Response by Adenosine A1 Receptors , 2009, The Journal of Neuroscience.

[77]  Jiang-Fan Chen,et al.  Genetic inactivation of adenosine A2A receptors attenuates acute traumatic brain injury in the mouse cortical impact model , 2009, Experimental Neurology.

[78]  Thea Mulder-Krieger,et al.  A series of 2,4-disubstituted quinolines as a new class of allosteric enhancers of the adenosine A3 receptor. , 2009, Journal of medicinal chemistry.

[79]  A. Knight,et al.  Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. , 2009, Journal of medicinal chemistry.

[80]  B. Fredholm,et al.  Decreased behavioral activation following caffeine, amphetamine and darkness in A3 adenosine receptor knock-out mice , 2008, Physiology & Behavior.

[81]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[82]  B. Fredholm,et al.  Adenosine A1 receptors regulate lipolysis and lipogenesis in mouse adipose tissue-interactions with insulin. , 2008, European journal of pharmacology.

[83]  J. P. Petzer,et al.  Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. , 2008, Bioorganic & medicinal chemistry.

[84]  B. Fredholm,et al.  Adenosine induces airway hyperresponsiveness through activation of A3 receptors on mast cells. , 2008, The Journal of allergy and clinical immunology.

[85]  G. Shaked,et al.  Anti-Inflammatory Preconditioning by Agonists of Adenosine A1 Receptor , 2008, PloS one.

[86]  K. Jacobson,et al.  Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. , 2008, Bioorganic & medicinal chemistry letters.

[87]  J. Tsien,et al.  A Critical Role of the Adenosine A2A Receptor in Extrastriatal Neurons in Modulating Psychomotor Activity as Revealed by Opposite Phenotypes of Striatum and Forebrain A2A Receptor Knock-Outs , 2008, The Journal of Neuroscience.

[88]  Ying Sun,et al.  Adenosine Promotes IL-6 Release in Airway Epithelia1 , 2008, The Journal of Immunology.

[89]  David A. Lustig,et al.  Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. , 2008, Journal of medicinal chemistry.

[90]  T. Eckle,et al.  A2B adenosine receptor dampens hypoxia-induced vascular leak. , 2008, Blood.

[91]  J. Downey,et al.  Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. , 2007, Journal of molecular and cellular cardiology.

[92]  B. Hocher,et al.  The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure , 2007, British journal of pharmacology.

[93]  M. Loza,et al.  Discovery and characterization of 4'-(2-furyl)-N-pyridin-3-yl-4,5'-bipyrimidin-2'-amine (LAS38096), a potent, selective, and efficacious A2B adenosine receptor antagonist. , 2007, Journal of medicinal chemistry.

[94]  B. Fredholm,et al.  Sex differences in mouse heart rate and body temperature and in their regulation by adenosine A1 receptors , 2007, Acta physiologica.

[95]  B. Fredholm,et al.  Eliminating the antilipolytic adenosine A1 receptor does not lead to compensatory changes in the antilipolytic actions of PGE2 and nicotinic acid , 2007, Acta physiologica.

[96]  C. Ledent,et al.  Cardioprotection by Ecto-5′-Nucleotidase (CD73) and A2B Adenosine Receptors , 2007, Circulation.

[97]  K. Klotz,et al.  [3H]HEMADO--a novel tritiated agonist selective for the human adenosine A3 receptor. , 2007, European journal of pharmacology.

[98]  A. IJzerman,et al.  ZM241385, DPCPX, MRS1706 Are Inverse Agonists with Different Relative Intrinsic Efficacies on Constitutively Active Mutants of the Human Adenosine A2B Receptor , 2007, Journal of Pharmacology and Experimental Therapeutics.

[99]  A. IJzerman,et al.  2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. , 2007, Journal of medicinal chemistry.

[100]  Linda Yip,et al.  ATP Release Guides Neutrophil Chemotaxis via P2Y2 and A3 Receptors , 2006, Science.

[101]  Xiaowei Jin,et al.  Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. , 2006, Journal of medicinal chemistry.

[102]  K. Klotz,et al.  Improving Potency, Selectivity, and Water Solubility of Adenosine A1 Receptor Antagonists: Xanthines Modified at Position 3 and Related Pyrimido[1,2,3‐cd]purinediones , 2006, ChemMedChem.

[103]  Pál Pacher,et al.  Adenosine receptors: therapeutic aspects for inflammatory and immune diseases , 2006, Nature Reviews Drug Discovery.

[104]  C. Müller,et al.  Characterization of human and rodent native and recombinant adenosine A2B receptors by radioligand binding studies , 2006, Purinergic Signalling.

[105]  M. Koupenova,et al.  The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. , 2006, The Journal of clinical investigation.

[106]  M. Sitkovsky,et al.  Adenosine A2a receptors induce heterologous desensitization of chemokine receptors. , 2006, Blood.

[107]  J. Falck,et al.  Adenosine2A receptor vasodilation of rat preglomerular microvessels is mediated by EETs that activate the cAMP/PKA pathway. , 2006, American journal of physiology. Renal physiology.

[108]  Xiaowei Jin,et al.  Norbornyllactone-substituted xanthines as adenosine A(1) receptor antagonists. , 2006, Bioorganic & medicinal chemistry.

[109]  Johannes Brussee,et al.  Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor. , 2006, Journal of medicinal chemistry.

[110]  B. Fredholm,et al.  Effect of modulating cardiac A1 adenosine receptor expression on protection with ischemic preconditioning. , 2006, American journal of physiology. Heart and circulatory physiology.

[111]  E. Kidd,et al.  Radioligand binding and functional responses of ligands for human recombinant adenosine A(3) receptors. , 2006, Autonomic & autacoid pharmacology.

[112]  P. Kochanek,et al.  Adenosine A1 Receptor Knockout Mice Develop Lethal Status Epilepticus after Experimental Traumatic Brain Injury , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[113]  J. Huidobro-Toro,et al.  The role of adenosine A2A and A3 receptors on the differential modulation of norepinephrine and neuropeptide Y release from peripheral sympathetic nerve terminals , 2006, Journal of neurochemistry.

[114]  K. Jacobson,et al.  Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.

[115]  A. IJzerman,et al.  Allosteric modulation, thermodynamics and binding to wild‐type and mutant (T277A) adenosine A1 receptors of LUF5831, a novel nonadenosine‐like agonist , 2006, British journal of pharmacology.

[116]  R. Cunha,et al.  Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat , 2005, Neuroscience.

[117]  C. Saper,et al.  Deletion of presynaptic adenosine A1 receptors impairs the recovery of synaptic transmission after hypoxia , 2005, Neuroscience.

[118]  S. Masino,et al.  Adenosine and ATP Link PCO2 to Cortical Excitability via pH , 2005, Neuron.

[119]  E. Vizi,et al.  Adenosine Augments IL-10 Production by Macrophages through an A2B Receptor-Mediated Posttranscriptional Mechanism1 , 2005, The Journal of Immunology.

[120]  K. Klotz,et al.  Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. , 2005, Biochemical pharmacology.

[121]  M. Morelli,et al.  New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. , 2005, Life sciences.

[122]  A. Nadeem,et al.  A Novel A1 Adenosine Receptor Antagonist, L-97-1 [3-[2-(4-Aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione], Reduces Allergic Responses to House Dust Mite in an Allergic Rabbit Model of Asthma , 2005, Journal of Pharmacology and Experimental Therapeutics.

[123]  A. Kurtz,et al.  Blood Pressure–Dependent Inhibition of Renin Secretion Requires A1 Adenosine Receptors , 2005, Hypertension.

[124]  Giovanni Piersanti,et al.  2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. , 2005, Journal of medicinal chemistry.

[125]  E. Jackson,et al.  Adenosine Inhibits PDGF-Induced Growth of Human Glomerular Mesangial Cells Via A2B Receptors , 2005, Hypertension.

[126]  R. Germack,et al.  Adenosine triggers preconditioning through MEK/ERK1/2 signalling pathway during hypoxia/reoxygenation in neonatal rat cardiomyocytes. , 2005, Journal of molecular and cellular cardiology.

[127]  B. Fredholm,et al.  Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine , 2005, Nature Neuroscience.

[128]  B. Fredholm,et al.  Mice lacking the adenosine A1 receptor have normal spatial learning and plasticity in the CA1 region of the hippocampus, but they habituate more slowly , 2005, Synapse.

[129]  G. Matherne,et al.  Myocardial function following cold ischemic storage is improved by cardiac-specific overexpression of A1-adenosine receptors. , 2005, Canadian journal of physiology and pharmacology.

[130]  P. Jenner Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease , 2005, Expert opinion on investigational drugs.

[131]  B. Fredholm,et al.  Luminal adenosine stimulates chloride secretion through A1 receptor in mouse jejunum. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[132]  J. Huidobro-Toro,et al.  A2B adenosine receptor mediates human chorionic vasoconstriction and signals through arachidonic acid cascade. , 2005, American journal of physiology. Heart and circulatory physiology.

[133]  R. Leurs,et al.  A "locked-on," constitutively active mutant of the adenosine A1 receptor. , 2005, European journal of pharmacology.

[134]  C. Müller,et al.  Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats , 2005, Psychopharmacology.

[135]  S. Dohi,et al.  Effects of adenosine agonist R-phenylisopropyl-adenosine on halothane anesthesia and antinociception in rats , 2005, Acta Pharmacologica Sinica.

[136]  B. Fredholm,et al.  Increased nociceptive response in mice lacking the adenosine A1 receptor , 2005, Pain.

[137]  K. Jacobson,et al.  2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors. , 2004, Biochemical pharmacology.

[138]  A. IJzerman,et al.  Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist‐specific G protein activation , 2004, British journal of pharmacology.

[139]  R. Germack,et al.  Activation of protein kinase B by adenosine A1 and A3 receptors in newborn rat cardiomyocytes. , 2004, Journal of molecular and cellular cardiology.

[140]  A. Iwashita,et al.  Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors. , 2004, Journal of pharmacological sciences.

[141]  B. Fredholm,et al.  Deletion of the adenosine A1 receptor gene does not alter neuronal damage following ischaemia in vivo or in vitro , 2004, The European journal of neuroscience.

[142]  C. Diniz,et al.  Facilitation of noradrenaline release by activation of adenosine A(2A) receptors triggers both phospholipase C and adenylate cyclase pathways in rat tail artery. , 2004, Cardiovascular research.

[143]  A. Castelhano,et al.  [3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors. , 2004, Biochemical pharmacology.

[144]  M. Loza,et al.  Synthesis and biological activity of new potential agonists for the human adenosine A2A receptor. , 2004, Journal of medicinal chemistry.

[145]  A. IJzerman,et al.  New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. , 2004, Journal of medicinal chemistry.

[146]  S. Muchnik,et al.  Presynaptic inhibition of spontaneous acetylcholine release induced by adenosine at the mouse neuromuscular junction , 2004, British journal of pharmacology.

[147]  B. Krämer,et al.  Gene expression of adenosine receptors along the nephron. , 2004, Kidney international.

[148]  M. W. George,et al.  Quantitative analysis of the formation and diffusion of A1-adenosine receptor-antagonist complexes in single living cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[149]  A. IJzerman,et al.  The mouse brain adenosine A1 receptor: functional expression and pharmacology. , 2004, European journal of pharmacology.

[150]  B. Fredholm,et al.  Involvement of A1 adenosine receptors in the acquisition of fertilizing capacity. , 2004, Journal of andrology.

[151]  B. Fredholm,et al.  Binding of the prototypical adenosine A2A receptor agonist CGS 21680 to the cerebral cortex of adenosine A1 and A2A receptor knockout mice , 2004, British journal of pharmacology.

[152]  K. Varani,et al.  Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. , 2004, Journal of medicinal chemistry.

[153]  G. Hartmann,et al.  Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. , 2004, Blood.

[154]  S. Nasr,et al.  A1 adenosine receptor knockout mice exhibit increased renal injury following ischemia and reperfusion. , 2004, American journal of physiology. Renal physiology.

[155]  C. Müller,et al.  Antinociceptive Effects of Novel A2B Adenosine Receptor Antagonists , 2004, Journal of Pharmacology and Experimental Therapeutics.

[156]  S. Schulz,et al.  Heterodimerization of Substance P and μ-Opioid Receptors Regulates Receptor Trafficking and Resensitization* , 2003, Journal of Biological Chemistry.

[157]  C. Dourish,et al.  Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson’s disease , 2003, Neurology.

[158]  P. Jenner,et al.  A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD , 2003, Neurology.

[159]  T. Sato,et al.  Involvement of adenosine A1 receptors in forced walking stress-induced analgesia in mice. , 2003, Methods and Findings in Experimental and Clinical Pharmacology.

[160]  B. Fredholm,et al.  Sleep and its homeostatic regulation in mice lacking the adenosine A1 receptor , 2003, Journal of Sleep Research.

[161]  B. Fredholm,et al.  Distribution of antinociceptive adenosine a1 receptors in the spinal cord dorsal horn, and relationship to primary afferents and neuronal subpopulations , 2003, Neuroscience.

[162]  C. Müller,et al.  Adenosine receptor agonists: from basic medicinal chemistry to clinical development , 2003, Expert opinion on emerging drugs.

[163]  Jiang-Fan Chen,et al.  The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment. , 2003, Drug news & perspectives.

[164]  H. Lipp,et al.  Emotional instability but intact spatial cognition in adenosine receptor 1 knock out mice , 2003, Behavioural Brain Research.

[165]  B. Fredholm,et al.  A1 adenosine receptors mediate hypoxia-induced ventriculomegaly , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[166]  W. Hauber,et al.  Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats , 2003, Synapse.

[167]  R. Cunha,et al.  Adenosine A3 receptors are located in neurons of the rat hippocampus , 2003, Neuroreport.

[168]  J. Fozard,et al.  Antagonist pharmacology of adenosine A2B receptors from rat, guinea pig and dog. , 2003, European journal of pharmacology.

[169]  R. J. Hill,et al.  Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. , 2003, American journal of physiology. Heart and circulatory physiology.

[170]  C. Ledent,et al.  Reduced startle habituation and prepulse inhibition in mice lacking the adenosine A2A receptor , 2003, Behavioural Brain Research.

[171]  J. Dickenson,et al.  Functional expression of adenosine A2A and A3 receptors in the mouse dendritic cell line XS-106. , 2003, European journal of pharmacology.

[172]  C. Saper,et al.  Focal Deletion of the Adenosine A1 Receptor in Adult Mice Using an Adeno-Associated Viral Vector , 2003, The Journal of Neuroscience.

[173]  M. Jacobson,et al.  References Subscriptions Permissions Email Alerts A Class I MHC-Restricted Recall Response to a Viral Peptide Is Highly Polyclonal Despite Stringent CDR3 Selection: Implications for Establishing Memory T Cell Repertoires in ''Real-World' ' Conditions , 2013 .

[174]  M. Tsai,et al.  Identification of A3 Receptor- and Mast Cell-Dependent and -Independent Components of Adenosine-Mediated Airway Responsiveness in Mice1 , 2003, The Journal of Immunology.

[175]  山本 秀一郎 Intrathecal adenosine A_1 receptor agonist attenuates hyperalgesia without inhibiting spinal glutamate release in the rat , 2003 .

[176]  Kenneth A. Jacobson,et al.  Behavioral Characterization of Mice Lacking the A3 Adenosine Receptor: Sensitivity to Hypoxic Neurodegeneration , 2003, Cellular and molecular neurobiology.

[177]  A. IJzerman,et al.  2,8-Disubstituted adenosine derivatives as partial agonists for the adenosine A2A receptor. , 2003, Bioorganic & medicinal chemistry.

[178]  V. Libri,et al.  Effect of the Adenosine A1 Receptor Agonist Gr79236 on Trigeminal Nociception with Blink Reflex Recordings in Healthy Human Subjects , 2003, Cephalalgia : an international journal of headache.

[179]  T. Ishikawa,et al.  Intrathecal Adenosine A1 Receptor Agonist Attenuates Hyperalgesia Without Inhibiting Spinal Glutamate Release in the Rat , 2003, Cellular and Molecular Neurobiology.

[180]  C. Ledent,et al.  Endogenous Adenosine Increases Coronary Flow by Activation of Both A2A and A2B Receptors in Mice , 2003, Journal of cardiovascular pharmacology.

[181]  Adriaan P IJzerman,et al.  N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor. , 2003, Journal of medicinal chemistry.

[182]  G. Breithardt,et al.  Altered sinus nodal and atrioventricular nodal function in freely moving mice overexpressing the A1 adenosine receptor. , 2003, American journal of physiology. Heart and circulatory physiology.

[183]  B. Fredholm,et al.  Aggravated Brain Damage After Hypoxic Ischemia in Immature Adenosine A2A Knockout Mice , 2003, Stroke.

[184]  G. Marks,et al.  Enhancement of rapid eye movement sleep in the rat by actions at A1 and A2a adenosine receptor subtypes with a differential sensitivity to atropine , 2003, Neuroscience.

[185]  K. Jacobson,et al.  2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors. , 2003, Bioorganic & medicinal chemistry.

[186]  V. D’Agati,et al.  A3 adenosine receptor knockout mice are protected against ischemia- and myoglobinuria-induced renal failure. , 2003, American journal of physiology. Renal physiology.

[187]  J. Headrick,et al.  Adenosine Receptor Subtypes Mediating Coronary Vasodilation in Rat Hearts , 2003, Journal of cardiovascular pharmacology.

[188]  M. Storr,et al.  Modulatory effect of adenosine receptors on the ascending and descending neural reflex responses of rat ileum , 2002, BMC Neuroscience.

[189]  C. Ledent,et al.  Low Ethanol Sensitivity and Increased Ethanol Consumption in Mice Lacking Adenosine A2A Receptors , 2002, The Journal of Neuroscience.

[190]  B. Fredholm,et al.  Decreased inflammatory pain due to reduced carrageenan-induced inflammation in mice lacking adenosine A3 receptors , 2002, Neuroscience.

[191]  Dirk Bier,et al.  Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. , 2002, Journal of medicinal chemistry.

[192]  M. Mocanu,et al.  Adenosine A(3) receptor activation protects the myocardium from reperfusion/reoxygenation injury. , 2002, American journal of physiology. Heart and circulatory physiology.

[193]  Richard A Stone,et al.  Knockout of A3 adenosine receptors reduces mouse intraocular pressure. , 2002, Investigative ophthalmology & visual science.

[194]  Kenneth A Jacobson,et al.  Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists. , 2002, Journal of medicinal chemistry.

[195]  B. Fredholm,et al.  Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate , 2002, The European journal of neuroscience.

[196]  L. Worrall,et al.  Induction of interleukin 8 release from the HMC-1 mast cell line: synergy between stem cell factor and activators of the adenosine A(2b) receptor. , 2002, Biochemical pharmacology.

[197]  K. Klotz,et al.  N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. , 2002, Journal of medicinal chemistry.

[198]  H. Yee,et al.  Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. , 2002, The American journal of pathology.

[199]  J. Shimada,et al.  KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist. , 2002, European journal of pharmacology.

[200]  K. Jacobson,et al.  Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. , 2002, Journal of medicinal chemistry.

[201]  R. Kukreja,et al.  Late preconditioning elicited by activation of adenosine A(3) receptor in heart: role of NF- kappa B, iNOS and mitochondrial K(ATP) channel. , 2002, Journal of molecular and cellular cardiology.

[202]  E. Piña,et al.  Regulation of glycogen metabolism in hepatocytes through adenosine receptors. Role of Ca2+ and cAMP. , 2002, European journal of pharmacology.

[203]  C. Müller,et al.  1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists. , 2002, Journal of medicinal chemistry.

[204]  A. IJzerman,et al.  2,5'-Disubstituted adenosine derivatives: evaluation of selectivity and efficacy for the adenosine A(1), A(2A), and A(3) receptor. , 2002, Journal of medicinal chemistry.

[205]  A. Ohta,et al.  Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage , 2001, Nature.

[206]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[207]  T. Scammell,et al.  An adenosine A2a agonist increases sleep and induces Fos in ventrolateral preoptic neurons , 2001, Neuroscience.

[208]  I. Biaggioni,et al.  Inhibition of human mast cell activation with the novel selective adenosine A(2B) receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)(2). , 2001, Biochemical pharmacology.

[209]  B. Fredholm,et al.  Abolished tubuloglomerular feedback and increased plasma renin in adenosine A1 receptor-deficient mice. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[210]  Jianjing Xue,et al.  Differential gene expression of adenosine A1, A2a, A2b, and A3 receptors in the human enteric nervous system , 2001, The Journal of comparative neurology.

[211]  Q. Dong,et al.  Overexpression of the A1 adenosine receptor in adipose tissue protects mice from obesity‐related insulin resistance , 2001, Diabetes, obesity & metabolism.

[212]  Z. Yang,et al.  Targeted deletion of A(3) adenosine receptors improves tolerance to ischemia-reperfusion injury in mouse myocardium. , 2001, American journal of physiology. Heart and circulatory physiology.

[213]  Tianxin Yang,et al.  Mediation of tubuloglomerular feedback by adenosine: Evidence from mice lacking adenosine 1 receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[214]  B. Fredholm,et al.  Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[215]  T. Skalak,et al.  Selective A(2A) adenosine receptor activation reduces skin pressure ulcer formation and inflammation. , 2001, American journal of physiology. Heart and circulatory physiology.

[216]  C. Allegrucci,et al.  Stimulation by N6-Cyclopentyladenosine of A1 Adenosine Receptors, Coupled to Gαi2 Protein Subunit, Has a Capacitative Effect on Human Spermatozoa1 , 2001, Biology of reproduction.

[217]  A. Ngai,et al.  Receptor subtypes mediating adenosine-induced dilation of cerebral arterioles. , 2001, American journal of physiology. Heart and circulatory physiology.

[218]  J. Mcpherson,et al.  Adenosine A2A Receptor Stimulation Reduces Inflammation and Neointimal Growth in a Murine Carotid Ligation Model , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[219]  Alexandre de Mendonça,et al.  A functional role for adenosine A3 receptors: modulation of synaptic plasticity in the rat hippocampus , 2001, Neuroscience Letters.

[220]  W. Bao,et al.  Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. , 2001, Journal of molecular and cellular cardiology.

[221]  K. Jacobson,et al.  [3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors. , 2001, Biochemical pharmacology.

[222]  Mauro Papotti,et al.  Immunohistochemical localization of adenosine A1 receptors in human brain regions , 2001, Neuroscience Letters.

[223]  A. IJzerman,et al.  Why are A(2B) receptors low-affinity adenosine receptors? Mutation of Asn273 to Tyr increases affinity of human A(2B) receptor for 2-(1-Hexynyl)adenosine. , 2000, Molecular pharmacology.

[224]  F. Fazio,et al.  Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using positron emission tomography. , 2000, Journal of medicinal chemistry.

[225]  A. Masamune,et al.  Activation of adenosine A1-receptor pathway induces edema formation in the pancreas of rats. , 2000, Gastroenterology.

[226]  C. Lluis,et al.  Immunolocalization of A1 Adenosine Receptors in Mammalian Spermatozoa , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[227]  B. Fredholm,et al.  Human adenosine A(1), A(2A), A(2B), and A(3) receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. , 2000, Molecular pharmacology.

[228]  K. Jacobson,et al.  Site-directed mutagenesis studies of human A(2A) adenosine receptors: involvement of glu(13) and his(278) in ligand binding and sodium modulation. , 2000, Biochemical pharmacology.

[229]  E. Ongini,et al.  Dose and time effects of caffeine intake on human platelet adenosine A(2A) receptors : functional and biochemical aspects. , 2000, Circulation.

[230]  C. Müller,et al.  Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes--a new, selective antagonist radioligand for A(2A) adenosine receptors. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[231]  A. IJzerman,et al.  Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A(3) receptor. , 2000, Journal of medicinal chemistry.

[232]  K. Klotz,et al.  [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. , 2000, Molecular pharmacology.

[233]  S. Rivkees,et al.  A1 adenosine receptor activation increases adipocyte leptin secretion. , 2000, Endocrinology.

[234]  D. Standaert,et al.  Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A2A adenosine receptors , 2000, Neuroscience.

[235]  H. Gavras,et al.  A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice. , 2000, Biochimica et biophysica acta.

[236]  K. Jacobson,et al.  Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. , 2000, Journal of medicinal chemistry.

[237]  Beverly H. Koller,et al.  Disruption of the A3 Adenosine Receptor Gene in Mice and Its Effect on Stimulated Inflammatory Cells* , 2000, The Journal of Biological Chemistry.

[238]  G. Spalluto,et al.  Synthesis and preliminary biological evaluation of [3H]-MRE 3008-F20: the first high affinity radioligand antagonist for the human A3 adenosine receptors. , 2000, Bioorganic & medicinal chemistry letters.

[239]  C. Franceschi,et al.  Activation of the A3 adenosine receptor affects cell cycle progression and cell growth , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[240]  M. Jacobson,et al.  Adenosine and inosine increase cutaneous vasopermeability by activating A(3) receptors on mast cells. , 2000, The Journal of clinical investigation.

[241]  K. Klotz,et al.  Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. , 2000, Journal of medicinal chemistry.

[242]  V. Vallon,et al.  Adenosine formed by 5'-nucleotidase mediates tubuloglomerular feedback. , 2000, The Journal of clinical investigation.

[243]  P. Svenningsson,et al.  Distribution, biochemistry and function of striatal adenosine A2A receptors , 1999, Progress in Neurobiology.

[244]  K. Jacobson,et al.  Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors. , 1999, Drug design and discovery.

[245]  M. Moskowitz,et al.  A2A Adenosine Receptor Deficiency Attenuates Brain Injury Induced by Transient Focal Ischemia in Mice , 1999, The Journal of Neuroscience.

[246]  J. Xaus,et al.  Adenosine inhibits macrophage colony-stimulating factor-dependent proliferation of macrophages through the induction of p27kip-1 expression. , 1999, Journal of immunology.

[247]  J. Linden,et al.  Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. , 1999, Molecular pharmacology.

[248]  A. IJzerman,et al.  Allosteric modulation of the adenosine A(1) receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. , 1999, Journal of medicinal chemistry.

[249]  E. Ongini,et al.  Caffeine alters A2A adenosine receptors and their function in human platelets. , 1999, Circulation.

[250]  T. Maeda,et al.  Region‐dependent difference in the sleep‐promoting potency of an adenosine A2A receptor agonist , 1999, The European journal of neuroscience.

[251]  C. Ezeamuzie,et al.  Adenosine A3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release , 1999, British journal of pharmacology.

[252]  K. Jacobson,et al.  1,3‐dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors , 1999, Drug development research.

[253]  K. Ravid,et al.  Characterization of the mouse A3 adenosine receptor gene: exon/intron organization and promoter activity. , 1999, Genomics.

[254]  T. Cocks,et al.  Adenosine mediates relaxation of human small resistance‐like coronary arteries via A2B receptors , 1999, British journal of pharmacology.

[255]  F. Pedata,et al.  Striatal A2A adenosine receptors differentially regulate spontaneous and K+-evoked glutamate release in vivo in young and aged rats. , 1999, Neuroreport.

[256]  M. Mirabet,et al.  Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation. , 1999, Journal of cell science.

[257]  S. Rivkees,et al.  Identification of the Adenine Binding Site of the Human A1 Adenosine Receptor* , 1999, The Journal of Biological Chemistry.

[258]  P. Schofield,et al.  Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and mutant adenosine A1 receptors. , 1998, Biochemical pharmacology.

[259]  J. Linden,et al.  Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system , 1998, The Journal of comparative neurology.

[260]  L. Berrino,et al.  The role of A3 adenosine receptors in central regulation of arterial blood pressure , 1998, British journal of pharmacology.

[261]  A. IJzerman,et al.  A novel class of adenosine A3 receptor ligands. 2. Structure affinity profile of a series of isoquinoline and quinazoline compounds. , 1998, Journal of medicinal chemistry.

[262]  A. IJzerman,et al.  A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives. , 1998, Journal of medicinal chemistry.

[263]  G. Spalluto,et al.  A2A-adenosine receptor reserve for coronary vasodilation. , 1998, Circulation.

[264]  S. Moro,et al.  Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. , 1998, Journal of medicinal chemistry.

[265]  O. Hayaishi,et al.  Involvement of adenosine A2A receptor in sleep promotion. , 1998, European journal of pharmacology.

[266]  J. Marshall,et al.  Role of adenosine and its receptors in the vasodilatation induced in the cerebral cortex of the rat by systemic hypoxia , 1998, The Journal of physiology.

[267]  C. Martini,et al.  2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies. , 1998, Journal of medicinal chemistry.

[268]  J. Sawynok,et al.  Antinociception by adenosine analogs and inhibitors of adenosine metabolism in an inflammatory thermal hyperalgesia model in the rat , 1998, Pain.

[269]  B. Fredholm,et al.  Comparative pharmacology of human adenosine receptor subtypes – characterization of stably transfected receptors in CHO cells , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[270]  J. Linden,et al.  Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor. , 1997, Molecular pharmacology.

[271]  R. Leurs,et al.  Heterologous expression of rat epitope‐tagged histamine H2 receptors in insect Sf9 cells , 1997, British journal of pharmacology.

[272]  Hiroshi Kase,et al.  Adenosine A2A antagonists with potent anti-cataleptic activity , 1997 .

[273]  A. Sollevi,et al.  Intrathecal Adenosine Analog Administration Reduces Substance P in Cerebrospinal Fluid Along with Behavioral Effects That Suggest Antinociception in Rats , 1997, Anesthesia and analgesia.

[274]  K. Jacobson,et al.  Pharmacological characterization of novel A3 adenosine receptor-selective antagonists , 1997, Neuropharmacology.

[275]  P. Schofield,et al.  Cloning, characterisation and chromosomal assignment of the human adenosine A3 receptor (ADORA3) gene 1 GenBank™ accession numbers: L77729 and L77730. 1 , 1997, Neuroscience Research.

[276]  S. Schiffmann,et al.  Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor , 1997, Nature.

[277]  J. Linden,et al.  Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[278]  R. Lum,et al.  Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine. , 1997, Journal of medicinal chemistry.

[279]  B. Fredholm,et al.  Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]‐SCH 58261 , 1997, British journal of pharmacology.

[280]  G Burnstock,et al.  Towards a revised nomenclature for P1 and P2 receptors. , 1997, Trends in pharmacological sciences.

[281]  M. Olah Identification of A2a Adenosine Receptor Domains Involved in Selective Coupling to GS , 1997, The Journal of Biological Chemistry.

[282]  U. Schwabe,et al.  Characterization of a novel adenosine binding protein sensitive to cyclic AMP in rat brain cytosolic and particulate fractions. , 1996, Biochemical pharmacology.

[283]  K. Jacobson,et al.  6-phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists. , 1996, Journal of medicinal chemistry.

[284]  Stephen P. H. Alexander,et al.  Characterization of the human brain putative A2B adenosine receptor expressed in Chinese hamster ovary (CHO.A2B4) cells , 1996, British journal of pharmacology.

[285]  K. Jacobson,et al.  Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. , 1996, Journal of medicinal chemistry.

[286]  E. Ongini,et al.  The selective adenosine A2A receptor antagonist SCH 58261 discriminates between two different binding sites for [3H]-CGS 21680 in the rat brain , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

[287]  B. Stein,et al.  Adenosine Receptor Antagonists: Structures and Potential Therapeutic Applications , 1996, Current Pharmaceutical Design.

[288]  B. Fredholm,et al.  Pharmacology of adenosine A2A receptors. , 1996, Trends in pharmacological sciences.

[289]  E. Ongini,et al.  Labeling of A2A adenosine receptors in human platelets by use of the new nonxanthine antagonist radioligand [3H]SCH 58261. , 1996, The Journal of pharmacology and experimental therapeutics.

[290]  K. Jacobson,et al.  Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors. , 1996, Journal of medicinal chemistry.

[291]  P. Schofield,et al.  Characterization and chromosomal localization of the human A2a adenosine receptor gene: ADORA2A. , 1996, Biochemical and biophysical research communications.

[292]  O. Hayaishi,et al.  Promotion of sleep mediated by the A2a-adenosine receptor and possible involvement of this receptor in the sleep induced by prostaglandin D2 in rats. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[293]  K. Jacobson,et al.  Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. , 1996, Journal of medicinal chemistry.

[294]  G. Firestein,et al.  Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. , 1996, Journal of immunology.

[295]  M. Edbrooke,et al.  Cloning and characterisation of the human adenosine A3 receptor gene , 1996, FEBS letters.

[296]  K. Varani,et al.  Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]‐CGS 21680 binding , 1996, British journal of pharmacology.

[297]  Y. Chern,et al.  Characterization of the rat A2a adenosine receptor gene. , 1996, DNA and cell biology.

[298]  J. Fozard,et al.  Mast cell degranulation following adenosine A3 receptor activation in rats. , 1996, European journal of pharmacology.

[299]  C. Darimont,et al.  Changes in adenosine A1- and A2-receptor expression during adipose cell differentiation , 1996, Molecular and Cellular Endocrinology.

[300]  G. Spalluto,et al.  Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors. , 1996, Journal of medicinal chemistry.

[301]  B. Fredholm,et al.  Evidence for high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

[302]  R. Wysocki,et al.  Characterization of 8-(N-methylisopropyl)amino-N6-(5'-endohydroxy- endonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors. , 1996, The Journal of pharmacology and experimental therapeutics.

[303]  J. Gusella,et al.  Characterization and Expression of the Human A2a Adenosine Receptor Gene , 1996, Journal of neurochemistry.

[304]  P. Popoli,et al.  Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. , 1995, European journal of pharmacology.

[305]  K. Jacobson,et al.  125I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor. , 1995, Molecular pharmacology.

[306]  M. Hohenegger,et al.  Species differences in A1 adenosine receptor/G protein coupling: identification of a membrane protein that stabilizes the association of the receptor/G protein complex. , 1995, Molecular pharmacology.

[307]  I. Biaggioni,et al.  Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. , 1995, The Journal of clinical investigation.

[308]  M. Danhof,et al.  Deoxyribose analogues of N6‐cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo , 1995, British journal of pharmacology.

[309]  E. Jackson,et al.  Selective A1 adenosine receptor antagonism augments beta-adrenergic-induced renin release in vivo. , 1995, The American journal of physiology.

[310]  Y. Okada,et al.  Adenosine facilitates in vivo neurotransmission in the superior colliculus of the rat. , 1995, Journal of neurophysiology.

[311]  E. Wong,et al.  Enhancement of adenosine A1 receptor functions by benzoylthiophenes in guinea pig tissues in vitro , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[312]  T. Palmer,et al.  Adenosine receptors , 1995, Neuropharmacology.

[313]  T. Palmer,et al.  Differential Interaction with and Regulation of Multiple G-proteins by the Rat A3 Adenosine Receptor (*) , 1995, The Journal of Biological Chemistry.

[314]  K. Jacobson,et al.  A3-adenosine receptors: design of selective ligands and therapeutic prospects. , 1995, Drugs of the future.

[315]  Stephen P. H. Alexander,et al.  Adenosine receptor-induced cyclic AMP generation and inhibition of 5-hydroxytryptamine release in human platelets. , 1995, British journal of clinical pharmacology.

[316]  J. Wess,et al.  Site-directed Mutagenesis Identifies Residues Involved in Ligand Recognition in the Human A2a Adenosine Receptor (*) , 1995, The Journal of Biological Chemistry.

[317]  M. Jacobson,et al.  Cloning and chromosomal localization of the human A2b adenosine receptor gene (ADORA2B) and its pseudogene. , 1995, Genomics.

[318]  K. Jacobson,et al.  "Cleavable trifunctional" approach to receptor affinity labeling: chemical regeneration of binding to A1-adenosine receptors. , 1995, Bioconjugate chemistry.

[319]  E. Ongini,et al.  Modeling hemodynamic profiles by telemetry in the rat. A study with A1 and A2a adenosine agonists. , 1995, Hypertension.

[320]  B. Fredholm,et al.  Further characterization of the binding of the adenosine receptor agonist [3H]CGS 21680 to rat brain using autoradiography , 1995, Neuropharmacology.

[321]  J. Linden,et al.  The allosteric enhancer, PD 81,723, stabilizes human A1 adenosine receptor coupling to G proteins. , 1995, Biochimica et biophysica acta.

[322]  B B Fredholm,et al.  Astra Award Lecture. Adenosine, adenosine receptors and the actions of caffeine. , 1995, Pharmacology & toxicology.

[323]  A. Strosberg,et al.  Species difference in the G protein selectivity of the human and bovine A1-adenosine receptor. , 1994, The Journal of biological chemistry.

[324]  S. Rivkees Localization and characterization of adenosine receptor expression in rat testis. , 1994, Endocrinology.

[325]  P. Strong,et al.  Characterization of the adenosine receptors mediating hypothermia in the conscious mouse , 1994, British journal of pharmacology.

[326]  K. Jacobson,et al.  2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. , 1994, Journal of medicinal chemistry.

[327]  K. Jacobson,et al.  Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding. Analysis of chimeric A1/A3 adenosine receptors. , 1994, The Journal of biological chemistry.

[328]  K. Jacobson,et al.  A binding site model and structure-activity relationships for the rat A3 adenosine receptor. , 1994, Molecular pharmacology.

[329]  G Burnstock,et al.  Nomenclature and Classification of Purinoceptors* , 2005 .

[330]  C. Müller,et al.  Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A1- and A2-adenosine receptor antagonists. , 1994, Journal of medicinal chemistry.

[331]  D. Marquardt,et al.  Cloning of two adenosine receptor subtypes from mouse bone marrow-derived mast cells. , 1994, Journal of immunology.

[332]  Stephen P. H. Alexander,et al.  Coupling of a transfected human brain A1 adenosine receptor in CHO‐K1 cells to calcium mobilisation via a pertussis toxin‐sensitive mechanism , 1994, British journal of pharmacology.

[333]  J. Daly,et al.  Functional characterization of the A2b adenosine receptor in NIH 3T3 fibroblasts. , 1994, Biochemical pharmacology.

[334]  P. Schofield,et al.  A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding. , 1994, The Journal of biological chemistry.

[335]  G. Stiles,et al.  Characterization of the human A1 adenosine receptor gene. Evidence for alternative splicing. , 1994, The Journal of biological chemistry.

[336]  J. Linden,et al.  Molecular cloning and characterization of the human A3 adenosine receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[337]  C. Müller,et al.  Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors. , 1993, Journal of medicinal chemistry.

[338]  B. Fredholm,et al.  The binding of the adenosine A2 receptor selective agonist [3H]CGS 21680 to rat cortex differs from its binding to rat striatum. , 1993, European journal of pharmacology.

[339]  G. Firestein,et al.  cDNA cloning and sequence analysis of the human A3 adenosine receptor. , 1993, Biochimica et biophysica acta.

[340]  T. Stone,et al.  Mediation of the neuroprotective action of R‐phenylisopropyladenosine through a centrally located adenosine A1 receptor , 1993, British journal of pharmacology.

[341]  K. Jacobson,et al.  Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. , 1993, Journal of medicinal chemistry.

[342]  R. Vestal,et al.  Cardiac functional responses to adenosine by PD 81,723, an allosteric enhancer of the adenosine A1 receptor. , 1993, The American journal of physiology.

[343]  S. Heckers,et al.  Adenosine A1 receptors in human hippocampus: inhibition of [3H]8-cyclopentyl-1,3-dipropylxanthine binding by antagonist drugs , 1993, Neuroscience Letters.

[344]  A. Townsend-Nicholson,et al.  Molecular cloning and characterisation of a human brain A1 adenosine receptor cDNA. , 1992, Brain research. Molecular brain research.

[345]  S. Hurt,et al.  [3H]2-phenylaminoadenosine ([3H]CV 1808) labels a novel adenosine receptor in rat brain. , 1992, The Journal of pharmacology and experimental therapeutics.

[346]  J. Dumont,et al.  Cloning and functional characterization of a human A1 adenosine receptor. , 1992, Biochemical and biophysical research communications.

[347]  T J Furlong,et al.  Molecular characterization of a human brain adenosine A2 receptor. , 1992, Brain research. Molecular brain research.

[348]  J. Shine,et al.  Molecular cloning and expression of an adenosine A2b receptor from human brain. , 1992, Biochemical and biophysical research communications.

[349]  G. Stiles,et al.  Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[350]  Richard J. Miller,et al.  Inhibition of quantal transmitter release in the absence of calcium influx by a G protein-linked adenosine receptor at hippocampal synapses , 1992, Neuron.

[351]  S. Rivkees,et al.  Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor subtype. , 1992, Molecular endocrinology.

[352]  B. Fredholm,et al.  Glucocorticoid receptor activation leads to up-regulation of adenosine A1 receptors and down-regulation of adenosine A2 responses in DDT1 MF-2 smooth muscle cells. , 1991, Molecular pharmacology.

[353]  C. Gerfen,et al.  Cloning and expression of an A1 adenosine receptor from rat brain. , 1991, Molecular pharmacology.

[354]  C. Müller,et al.  Caffeine analogs: structure-activity relationships at adenosine receptors. , 1991, Pharmacology.

[355]  K. Klotz,et al.  Comparison of A1 adenosine receptors in brain from different species by radioligand binding and photoaffinity labelling , 1991, Naunyn-Schmiedeberg's Archives of Pharmacology.

[356]  J. Fergus,et al.  Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. , 1990, Molecular pharmacology.

[357]  G. Sutherland,et al.  Binding of the Adenosine A2 Receptor Ligand [3H]CGS 21680 to Human and Rat Brain: Evidence for Multiple Affinity Sites , 1990, Journal of neurochemistry.

[358]  P. Hartvig,et al.  Effects of Intrathecal Injection of the Adenosine Receptor Agonists R‐Phenylisopropyl‐Adenosine and N‐Ethylcarboxamide‐Adenosine on Nociception and Motor Function in the Rat , 1990, Anesthesia and analgesia.

[359]  J. Schnermann,et al.  Inhibition of tubuloglomerular feedback during adenosine1 receptor blockade. , 1990, The American journal of physiology.

[360]  M. Williams,et al.  [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. , 1989, The Journal of pharmacology and experimental therapeutics.

[361]  C. O'shaughnessy,et al.  A1 adenosine receptor-mediated block of epileptiform activity induced in zero magnesium in rat neocortex in vitro , 1988, Epilepsy Research.

[362]  A. Dolphin,et al.  Pertussis toxin reverses adenosine inhibition of neuronal glutamate release , 1985, Nature.

[363]  R. D. Murray,et al.  Effects of adenosine receptor agonists in the isolated, perfused rat kidney. , 1984, The American journal of physiology.

[364]  R F Bruns,et al.  Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. , 1980, Canadian journal of physiology and pharmacology.

[365]  L. Dušek,et al.  Erythropoiesis- and thrombopoiesis-characterizing parameters in adenosine A3 receptor knock-out mice. , 2013, Physiological research.

[366]  E. Elzein,et al.  A1 adenosine receptor agonists and their potential therapeutic applications. , 2008, Expert opinion on investigational drugs.

[367]  C. Müller,et al.  Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders. , 2007, Recent patents on CNS drug discovery.

[368]  Courtney M. Lappas,et al.  A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. , 2005, Journal of immunology.

[369]  B. Fredholm,et al.  Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. , 2005, Annual review of pharmacology and toxicology.

[370]  N. Maulik,et al.  Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation. , 2005, American journal of physiology. Heart and circulatory physiology.

[371]  B. Fredholm,et al.  Adenosine A3 receptor-mediated regulation of p38 and extracellular-regulated kinase ERK1/2 via phosphatidylinositol-3'-kinase. , 2004, Biochemical pharmacology.

[372]  I. Biaggioni,et al.  A(2B) adenosine receptors increase cytokine release by bronchial smooth muscle cells. , 2004, American journal of respiratory cell and molecular biology.

[373]  M. Ochi,et al.  Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. , 2003, Neurology.

[374]  K. Ravid,et al.  Overexpression of A3 adenosine receptors in smooth, cardiac, and skeletal muscle is lethal to embryos. , 2002, Microvascular research.

[375]  C. Müller,et al.  [(3)H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-purin-5-one ([(3)H]PSB-11), a novel high-affinity antagonist radioligand for human A(3) adenosine receptors. , 2002, Bioorganic & medicinal chemistry letters.

[376]  M. Parmentier,et al.  Absence of the adenosine A(2A) receptor or its chronic blockade decrease ethanol withdrawal-induced seizures in mice. , 2001, Neuropharmacology.

[377]  J. Linden,et al.  Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists. , 2001, British journal of pharmacology.

[378]  Stephen P. H. Alexander,et al.  [(3)H]ZM241385--an antagonist radioligand for adenosine A(2A) receptors in rat brain. , 2001, European Journal of Pharmacology.

[379]  E. Ongini,et al.  Dose and Time Effects of Caffeine Intake on Human Platelet Adenosine A 2 A Receptors Functional and Biochemical Aspects , 2000 .

[380]  P. Svenningsson,et al.  Adenosine A(2A) receptors are colocalized with and activate g(olf) in rat striatum. , 2000, Molecular pharmacology.

[381]  C. Müller A2A adenosine receptor antagonists - future drugs for Parkinson's disease? , 2000 .

[382]  B. Fredholm,et al.  Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. , 1999, Biochemical pharmacology.

[383]  B. Fredholm,et al.  Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[384]  B. Fredholm,et al.  Signaling via A2A adenosine receptor in four PC12 cell clones , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[385]  A. IJzerman,et al.  5'-substituted adenosine analogs as new high-affinity partial agonists for the adenosine A1 receptor. , 1998, Journal of medicinal chemistry.

[386]  D. J. Triggle,et al.  Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for a 3 receptors , 1998 .

[387]  G. Stiles,et al.  Adenosine receptor subtypes: characterization and therapeutic regulation. , 1995, Annual review of pharmacology and toxicology.

[388]  K. Jacobson,et al.  Adenosine Receptors:Selective Agonists and Antagonists , 1995 .

[389]  J. Daly,et al.  Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors. , 1993, Pharmacology.

[390]  J. Koopman,et al.  Differences in the intestinal microflora of normal and dystrophic BIO 8262 Nij Syrian hamsters. , 1990, Zeitschrift fur Versuchstierkunde.